Cydem system [Beckman Coulter Life Sciences]
According to a representative from Beckman Coulter Life Sciences, the new platform was created to streamline the identification of top-performing clones during cell line development for monoclonal antibodies, recognizing that CHO cells remain the primary host system for this type of work.
The Cydem VT system offers up to 90% reduction in manual steps and 96 parallel bioreactor capacity, according to a product announcement. It also supports three-plus days of automated operation. The system’s architecture incorporates individual gassing control for each bioreactor, enabling precise pH-controlled, fed-batch cultivation protocols. The integrated analytical suite performs on-deck determination of critical quality attributes, including cell concentration, viability assessment, and titer concentration measurements. This integration of parallel microbioreactor control with automated analytics could address significant bottlenecks in cell line development workflows. The platform’s automated operations support three-plus days of walk-away time, with up to 90% reduction in manual interventions compared to traditional screening methods.
Beckman Coulter notes that the integration of parallel microbioreactor control with automated analytics could address significant bottlenecks in cell line development workflows. The product announcement notes that it “provides labs with more reliable clones compared to traditional methods, along with better cultivation conditions that are closer to biomanufacturing production.”
Filed Under: Biologics, Cell & gene therapy, Drug Discovery and Development
